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CTGF expression in mesangial cells: Involvement of SMADs, As a whole, fibrosis is one of the largest groups of disor-
MAP kinase, and PKC. ders for which there is no effective therapy, in part be-
Background. The induction of excess matrix in renal fibrosis cause the mechanism underlying these disorders remainsseems to be mediated, at least in part, by the transforming growth
elusive and, as a consequence, a paucity of molecularfactor- (TGF-)-mediated induction of connective tissue growth
targets exists around which to base anti-fibrotic therapies.factor (CTGF) in mesangial cells.
Methods. By examining CTGF protein and mRNA expression Studies show that glucose can induce matrix synthesis,
and promoter activity in the presence or absence of TGF- or at least in part, by transforming growth factor- (TGF-)
inhibitors, the signaling pathways controlling basal and TGF-– [reviewed in 1–3]. A high glucose concentration inducesinduced CTGF expression in mesangial cells were investigated.
TGF- mRNA and protein, and neutralizing antibodiesResults. TGF- enhances CTGF mRNA and protein expres-
to TGF- reduce the ability of high glucose to stimulatesion in mesangial cells. Mutation of a consensus SMAD binding
element in the CTGF promoter completely abolished TGF-– matrix synthesis; in addition, treatment of diabetic mice
induced CTGF expression and reduced basal CTGF expres- with neutralizing TGF- antibodies attenuate the increase
sion. The previously identified basal control element-1 (BCE-1) in extracellular matrix observed in these animals [4; re-site, but not Sp1 contributes to basal CTGF promoter activity.
viewed in 2, 3]. These data collectively suggest that theRas/MEK/ERK, protein kinase C (PKC) and tyrosine kinase
initiation of kidney fibrosis is mediated, at least in part,activity also contribute to basal and TGF-–induced CTGF
promoter activity in cultured mesangial cells. by TGF-.
Conclusions. The TGF-–induction of CTGF in mesangial However, TGF-might not be a clinically advantageous
cells requires SMADs and PKC/ras/MEK/ERK pathways.
target as it has many different effects on physiology ofSMADs are involved in basal CTGF expression, which presum-
the organism, for example TGF- influences the immuneably reflects the fact that mesangial cells express TGF- endog-
enously. TGF- also induces CTGF through ras/MEK/ERK. system and epithelial proliferation [5]. Plus, although
Inhibiting ras/MEK/ERK seems not to reduce phosphorylation TGF- is certainly implicated in the onset of fibrosis, at
(that is, activation) of SMADs, suggesting that SMADs, al- least in animal models of fibrosis [6], the role TGF-
though necessary, are insufficient for the TGF-–stimulation
plays in maintaining persistent fibrosis in human patientsof the CTGF promoter through ras/MEK/ERK. Thus, maximal
remains to be clarified [7]. Given these considerations,TGF- induction of CTGF requires synergy between SMAD
and ras/MEK/ERK signaling. blocking TGF- effects may have multiple effects on the
organism, and identification of a downstream effector of
TGF- signaling that is directly involved with the fibrotic
Wound healing requires de novo synthesis of connec- phenotype might be advantageous in developing selec-
tive tissue. If this process is not appropriately terminated, tive anti-fibrotic therapies.
fibrosis can occur, resulting in organ failure and death. Transforming growth factor- not only directly induces
collagen and matrix synthesis, but also induces expres-
sion of other biologically-active profibrotic mediators. One
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such protein is connective tissue growth factor (CTGF),fibrosis, SMADs, mitogen activated protein kinase, protein kinase C,
wound healing. which induces proliferation, collagen synthesis and che-
motaxis in mesenchymal cells [reviewed in 8, 9]. CTGFReceived for publication January 26, 2002
also promotes fibronectin synthesis in mesangial cellsand in revised form May 6, 2002
Accepted for publication May 10, 2002 [10–12] and seems to mediate at least part of TGF-–
induced collagen and fibronectin synthesis in renal fi- 2002 by the International Society of Nephrology
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broblasts [13]. CTGF is overexpressed in numerous fi- (JNK) [28–30]. A number of cell specific interactions
have been described between MAPK cascades and TGF-brotic disorders, including renal fibrosis [10, 14–17]. In
fact, levels of CTGF expression correlate with the sever- –driven SMAD signaling. For example, the response
of epithelial cells to TGF- involves the interaction ofity and progression of renal fibrosis [14, 18]. As a result,
CTGF is considered a useful molecular marker of the JNK and SMAD [31] and the induction of plasminogen
activator inhibitor by TGF- requires synergy betweenfibrotic response [reviewed in 8, 9, 19]. Although CTGF
has not yet been shown to directly induce renal fibrosis the Ras/MEK/ERK cascade and SMAD signaling [32].
However, it is unclear whether ras/MEK/Erk directlyin vivo, CTGF, when injected subcutaneously along with
TGF-, induces sustained dermal fibrosis in rats [20]. In affect SMAD activation or whether they modulate activ-
ity of the transcription factors that SMADs help recruitaddition, a small molecule inhibitor that blocks CTGF
expression in culture and in vivo alleviates symptoms of to the promoter. In short, SMADs may be necessary but
not sufficient for activation of target genes.fibrosis in scleroderma patients [21]. Thus, the overex-
pression of CTGF in fibrosis might explain in part the Recently, we have begun to investigate the mechanism
underlying the TGF-–induction of CTGF gene expres-persistent scarring that characterizes fibrotic disorders.
Consequently, targeting CTGF overexpression might be sion in dermal fibroblasts and have shown that this in-
volves a functional SMAD binding site in the CTGFa suitable method of selectively attacking fibrosis.
In normal fibroblasts, TGF- directly induces CTGF promoter [7, 23]. However, the control of CTGF expres-
sion in mesangial cells remains largely uninvestigated.expression [22] at least in part through elements in the
CTGF promoter [7, 23]. In fact, the control of CTGF Recently, the SMAD signaling pathway has been shown
to be functional in mesangial cells [33]. Our current re-gene expression is thought to lie chiefly at the level of
transcription [reviewed in 8]. Recently, it has been shown port examines the role that SMADs and ancillary signal-
ing pathways play in CTGF gene expression in culturedthat glucose can induce CTGF synthesis in mesangial
cells, at least in part, through TGF [15, 16, 24]. Given mesangial cells. We found that, although SMAD signal-
ing is constitutive in mesangial cells and is absolutelyCTGF’s status as both a marker and a mediator of fibro-
sis, examining the control of TGF-–induced CTGF ex- required for the ability of exogenously added TGF-
to induce CTGF, the ras/MEK/ERK pathway also ispression in mesangial cells should provide insights into
the molecular mechanism underlying the development required for this latter process while ras/MEK/ERK
seems not to affect SMAD activity directly.of kidney fibrosis.
In general, little is known about TGF- signaling in
the kidney or, in particular, about the control of TGF-
METHODS
–induced CTGF gene expression in mesangial cells.
DNA constructs and transfectionsHowever, studies employing other cell types identified
a central, general role of SMADs in the TGF-–induced The CTGF reporter deletion constructs used were as
previously described, and consist of segments of theexpression of target genes [reviewed in 25]. According to
current concepts regarding SMAD-dependent signaling, CTGF promoter lying between 805 and 17, 244 to
17, 166 to 17 and 110 to 17 subcloned intoSMADs themselves do not activate gene expression, but
instead are thought to act as transcriptional comodula- pSEAP2 basic (a system using secreted enhanced alka-
line phosphatase as a reporter molecule; Clontech; Palotors that help recruit transcription factors to the pro-
moter and thus help form an active transcriptional com- Alto, CA, USA) [7, 23]. Point mutations in the functional
Sp1 site were introduced (Stratagene, La Jolla, CA, USA)plex [reviewed in 26]. It is these recruited transcription
factors, which vary depending on the gene and cell type using as primers (Sigma Genosys, Poole, Dorset, UK)
5-GTATAAAAGCCTCGGGCCGCGGCCGCCCAof interest, that activate target gene expression in a spe-
cific fashion. The transcription factors that SMADs inter- AACTCACACAACAAC-3 and its antisense. Constructs
were sequenced to verify introduction of the correct mu-act with and recruit to the promoter can themselves be
the targets of other signaling pathways. In other words, tation. Constructs in which the SMAD and BCE ele-
ments were mutated to BamHI sites in the context ofthe diversity and specificity of the biological effects of
TGF- are due in part to the interaction of the general, the 805 to 17 construct were previously described
[7]. The SMAD 3, 4, 6 and 7 expression vectors wereubiquitous TGF-–stimulated SMAD signaling pathway
with other signaling pathways, the nature of which de- from Joan Massague (Rockefeller University, New York,
NY, USA), the dominant negative ras construct was pur-pends on the cell type or target gene of interest [27].
For example, in addition to the effects on SMAD phos- chased (Upstate Biotechnology, Lake Placid, NY, USA).
The dominant negative protein kinase  and  constructsphorylation, TGF- is able to signal via Ras and Rac
proteins, and activate certain mitogen activated protein were made by purchasing wild-type cDNAs encoding
these kinases (ATCC), subcloning them into an expres-kinases (MAPK) including the extracellular signal-regu-
lated kinases (ERK1 and 2), and Jun-N-terminal kinase sion vector (pUSE; Upstate Biotechnology) and mutat-
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ing their adenosine 5-triphosphate (ATP) binding sites cells were incubated with inhibitor for six hours before
analyzing for protein expression.(K to R) using a strategy outlined by Soh et al [34] and
an in vitro mutagenesis kit (Stratagene). The resultant
RT-PCRplasmids ( K368R and  K376R) were fully sequenced
Real-time reverse transcription-polymerase chain re-to verify introduction of the correct mutation.
action (RT-PCR) was performed essentially as describedTransfections and reporter assays were carried out
[37]. Total RNA from mesangial cells was isolated withusing lipofectamine plus (Invitrogen, Carlsbad, CA,
a Qiagen Rneasy kit (Qiagen Gmbh, Valencia, CA, USA).USA) as previously described [7, 23, 35], using 1 g of
To make cDNA, reverse transcriptase using Superscripta reporter construct and 0.25 g of a control CMV-
was used as described by the manufacturer (Life Tech-galactosidase plasmid (Clontech), which was used to ad-
nologies) by adding 2 L of Oligo dT primers to 3 gjust for differences in transfection efficiencies between
of total RNA in a volume of 20 L. After incubationsamples (Tropix). For assays in which the role of trans-
for five minutes at 72C, deoxynucleoside triphosphatesacting proteins was to be tested, 0.5 g of reporter and
(dNTPs), dithiothreitol (DTT), enzyme and 5	 buffer1 g of empty expression vector or expression vector
were added and samples were incubated for one hourencoding the protein of interest were used. TGF-1 was
at 37C. Amplification reactions were done in a 25 Lfrom R&D Systems (Minneapolis, MN, USA) or In-
reaction volume by combining 2.5 L cDNA, 2 L 1.5vitrogen. TGF-2 (Celtrix) also was used for some stud-
mol/L MgCl2, 2 L dNTPs, 1 L forward (5 pmol) andies and gave identical results to TGF-1. Before use for
1L reverse primer (5 pmol), 2.5L SybrGreen (Roche,experiments, TGF-s from different sources or lots were
Mannheim, Germany), 0.125 L TaqGold and 13.875compared to establish that their specific activities were
L milliQ water. Nucleotide sequences of primers were:equivalent as determined by their ability to induce CTGF
TATA binding protein (TBP) forward 5-GAA TAAprotein expression. Therefore, results using different
GAG AGC CAC GAA CAA CTG-3, TBP reverse 5-commercial sources and lots of TGF- are directly com-
CCC AGC TTC TGC ACA ACT CT-3, CTGF forwardparable. Inhibitors were added, at concentrations indi-
5-ATC CCT GCG ACC CAC ACA AG-3, CTGF re-cated, 45 minutes before addition of TGF-. Inhibitors
verse 5-CAA CTG CTT TGG AAG GAC TCG C-3.were: U0126 (Stratagene), mithramycin (Sigma) and
Amplification was carried out in a PE7700 (PE Biosys-genistein, herbimycin, PD98059, bisinolylmaleimide and
tems, Weiterstadt, Germany) PCR machine with an ini-Go 6983 (all from Calbiochem, La Jolla, CA, USA).
tial 10 minute step at 95C, followed by 40 cycles of 15Cells were incubated in the presence of inhibitor and/or
seconds at 95C and one minute at 60C. FluorescenceTGF- for 24 hours. Data presented are means (of at
was measured during the last 30 seconds of the 60 step.
least 6 replicates in at least 2 independent experiments) 

Each sample was analyzed in triplicate in three indepen-
SEM. Statistical analysis was performed by the Student dent experiments and a standard curve was constructed
unpaired test. P values less than 0.05 were considered of samples run in a twofold dilution series. Threshold
statistically significant. cycles (Ct values) were related to the standard curve.
Correlation coefficients were 0.99 and the slope of theCell culture, immunofluorescence staining and
standard curve was 3.14 for CTGF and 3.51 for TBP.Western blot analysis
A rat mesangial cell (MC) line was cultured as pre- SMAD phosphorylation study
viously described [12, 36]. Immunofluorescent staining A construct encoding FLAG-tagged SMAD3 (from
for CTGF was performed using a human anti-CTGF Joan Massague) was transfected into mesangial cells us-
antibody as previously described [35]. For Western blots, ing lipofectamine plus (1 g DNA/well). After a serum-
cells were cultured in Dulbecco’s modified Eagle’s me- starvation step in DMEM/0.5% FBS, cells were washed
dium (DMEM) with 20% fetal bovine serum (FBS; Life three times in PBS and were incubated for two hours
Technologies, Paisley, UK) until 80% confluence. When in phosphate-free DMEM plus 32P-orthophosphate (0.1
appropriate, cells were serum starved and treated with mCi/mL; NEN, Boston, MA, USA). Cells were then
5 ng/mL TGF-1 (R&D Systems or Invitrogen) as pre- incubated for 45 minutes in the presence or absence of
viously described [23, 35]. Media were harvested and inhibitor and treated with or without 25 ng/mL TGF-2
equal amounts were electrophoresed through a 12% so- for an additional 30 minutes. Cell layers were then
dium dodecyl sulfate (SDS)/polyacrylamide gel (Novex, washed extensively, harvested, and equal amounts of
San Diego, CA, USA) and blotted to nitrocellulose (Bio- radioactivity were subjected to immunoprecipitation with
Rad, Hercules, CA, USA). CTGF protein was detected anti-FLAG conjugated agarose (Sigma) as previously
as previously described [7, 23, 35]. Inhibitors were added, described [7]. Bound protein was then eluted in sample
at concentrations indicated, 45 minutes before the addi- buffer and subjected to SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE). Gels were then dried and sub-tion of TGF-. However, for the study with mithramycin,
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Adding to our results obtained with CTGF protein, the
addition of TGF- to mesangial cells resulted in an in-
duction of CTGF mRNA that was maximal four hours
later (Fig. 1B). Expression of CTGF mRNA was reduced
by 24 hours after TGF- addition (Fig. 1B). As expected,
mRNA induction preceded accumulation of CTGF pro-
tein in the media. CTGF protein accumulated in the
media even after the CTGF mRNA began to disappear,
reflecting that protein synthesis was delayed after mRNA
synthesis and that accumulated CTGF protein seemed
to be stable in the media for at least 24 hours after its
secretion.
CTGF expression in mesangial cells requires BCE-1
but does not require Sp1Fig. 1. Transforming growth factor- (TGF-) induces connective tis-
sue growth factor (CTGF) protein and mRNA in cultured rat mesangial After showing that TGF- could induce CTGF protein
cells. (A ) TGF- induces CTGF protein. Mesangial cells were cultured and mRNA in mesangial cells, we decided to determine,until 80% confluent, serum-starved for 18 hours, and then treated with
at least in part, if the TGF- induction of CTGF wasor without 5 ng/mL TGF-1 (as indicated) for 24 hours. Cell layers
were then harvested, and equal amounts of protein were subjected to conferred by sequences in the CTGF promoter. We rea-
SDS-PAGE and Western blotting with chicken anti-CTGF antibody soned that elements in the CTGF promoter would be[23]. (B ) TGF- induces CTGF mRNA. The experiment was performed
necessary for its induction in mesangial cells as it hasas in (A) except that RNA was harvested at various times (hours, as
indicated) after the addition of TGF-. RT-PCR was then conducted previously been shown using nuclear run-on experiments
as described in the Methods section for CTGF mRNA and TATA and promoter studies that the TGF- induction of CTGFbinding protein (TBP) as an internal control. Values shown are a ratio
in fibroblasts is controlled largely at the level of transcrip-between CTGF mRNA levels and TBP levels. Data represent averages

SEM of three independent experiments, each performed in triplicate. tion [7, 23, 38; reviewed in 8]. A description of putative
and known regulatory sequences in the CTGF promoter
has recently been published [39]; a description of regula-
tory sequences verified to be functional in human dermal
jected to autoradiography to detect labeled, phosphory- and mouse NIH 3T3 fibroblasts as well as the constructs
lated SMAD3. used to establish functionality of these sequences is
shown in Figure 2A (Leask et al, manuscript submitted
for publication) [7, 19, 23]. To determine if the abilityRESULTS
of TGF- to induce CTGF in mesangial cells was due,TGF- induces CTGF protein mRNA in mesangial cells
at least in part, to elevated CTGF promoter activity,
To determine if TGF- could induce CTGF synthesis mesangial cells were transfected with a SEAP reporter
in rat mesangial cells [12, 36], we placed equal numbers construct driven by a segment of the CTGF promoter
of mesangial cells into each well of a 6-well dish. Follow- spanning nucleotides 805 to 17 (Fig. 2A). This con-
ing an 18-hour serum-starvation step, cells were incu- struct had previously been shown to be responsive to
bated in the presence or absence of 5 ng/mL TGF-1 TGF- in fibroblasts [7, 19, 23]. After a serum starvation
for an additional 24 hours, and collected media. Equal step, cells were treated with 2.5 ng/mL TGF-1 for 24
amounts of media (25 L) were then subjected to SDS- hours. We found that the addition of TGF-1 to trans-
PAGE. Proteins were blotted onto nitrocellulose, and fected mesangial cells resulted in an induction of CTGF
CTGF protein was detected using Western blot analysis promoter activity (Fig. 2B). Thus, elevated CTGF pro-
with a chicken anti-CTGF antibody. CTGF protein was tein and mRNA synthesis upon TGF- treatment of
constitutively expressed in mesangial cells, and the addi- mesangial cells is due, in part, to elevated CTGF pro-
tion of TGF-1 resulted in further induction of CTGF moter activity and that this induction is mediated by
protein (Fig. 1A). sequences lying between nucleotides 805 and 17 of
To determine if the TGF- induction of CTGF protein the CTGF promoter.
was reflected by elevated synthesis of CTGF mRNA, To further elucidate the elements in the CTGF pro-
we performed a similar experiment, this time harvesting moter necessary for CTGF gene expression in mesangial
total RNA at various time points after the addition of cells, various CTGF promoter deletion and mutation
TGF-. Then, cDNA was generated from total RNA constructs were transfected into mesangial cells and as-
and subjected the cDNAs to RT-PCR with CTGF and sayed for reporter gene expression (Fig. 2A). Similar
TATA binding protein (TBP) primers to quantify ex- to our results in human dermal and mouse NIH 3T3
fibroblasts, mutation of the BCE-1 recognition sequencepression of CTGF relative to the TBP internal control.
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Fig. 3. Transfection of SMAD7, but not SMAD6, attenuates CTGF
promoter activity in mesangial cells with () or without ( ) TGF-.
FLCTGF/SEAP (0.5 g/well) was transfected with empty expression
vector, or expression vectors encoding SMAD6 or SMAD7 (1.0g each/
well) and expression of the SEAP reporter was evaluated as described in
the Methods section. Average expression values 
 SEM (N  6) are
shown. **Cotransfection of SMAD7 statistically significantly (P 0.01)
reduces basal and TGF-–induced CTGF promoter activity.
CTGF’s Sp1 site and TATA box showed essentially
background promoter activity (Fig. 2B). This result sug-
gested that CTGF’s Sp1 site might not be functional in
mesangial cells. To support this notion, mutation of the
CTGF promoter’s functional Sp1 binding site, shown to
be involved with basal but not TGF-–induced CTGF
promoter activity in fibroblasts had no effect on basal
or TGF-–induced CTGF promoter activity in mesangial
cells (Fig. 2B; Leask et al, manuscript submitted forFig. 2. Elements in the CTGF promoter that contribute to basal and
TGF-–induced expression in mesangial cells. (A ) Schematic diagram publication). To confirm this impression, Western blot
of promoter constructs used. Fragments of the CTGF promoter sub- analysis was used to test the ability of the Sp1 inhibitor
cloned upstream of the SEAP reporter were: 805 to 17 (805);
mithramycin [40] to reduce basal CTGF protein expres-244 to 17 (244); 166 to 17 (166); and 110 to 17 (110).
Constructs containing mutations in the regulatory elements in the con- sion in mesangial cells. The addition of mithramycin to
text of the FL construct were: SMAD mutant (SMAD), BCE-1 mutant cultured rat mesangial cells did not reduce CTGF protein
(BCE) and Sp1 mutant (Sp1). Note that the BCE-1 element was pre-
levels in this cell type (Fig. 3). Thus, although BCE-1viously termed the TGFRE [7], and was renamed to more accurately
reflect its role in basal CTGF promoter activity. An X denotes a mutated seemed necessary for basal CTGF promoter activity in
binding site. (B ) Expression of CTGF promoter constructs in cultured mesangial cells, Sp1 activity was not involved in CTGFmesangial cells with ( ) or without () TGF-. Constructs in (A)
promoter activity or gene expression in rat mesangial cells.were transfected into mesangial cells and reporter gene expression was
analyzed as described in the Methods section. Average expression val-
ues
 SEM (N 6) are shown. Mutation of the SMAD element reduces SMADs and CTGF gene expression in mesangial cells:
basal CTGF promoter activity as well as abolishes the TGF- induction SMAD activity is constitutive in mesangial cellsof CTGF. Mutation of the BCE-1 element reduces basal CTGF pro-
moter activity, whereas mutation of the Sp1 site functional in dermal Previously, we identified a functional SMAD binding
and NIH 3T3 fibroblasts (Leask et al, manuscript submitted for publica- site, CAGACGAA located between nucleotides 173tion) has no effect on CTGF promoter activity. **The CTGF promoter
and 166 in the CTGF promoter, which was necessarydeletion or mutation gives statistically significant (P  0.01) different
expression values relative to the full-length (805) construct 
 TGF-. for the TGF-–induction of CTGF in dermal and NIH
3T3 fibroblasts [7]. In our earlier study, this SMAD ele-
ment was shown to bind SMAD3 and 4 in a gel shift assay,
and mutation of this element abolished the TGF-–(formerly termed the TGFRE) [7, 19, 23, 38], resulted
induction of CTGF [7]. To determine if the CTGF pro-in a reduction of basal CTGF promoter activity while
moter’s SMAD binding element was necessary for thestill permitting a TGF- response (Fig. 2B). A promoter
TGF-–induction of CTGF in mesangial cells, we trans-deletion construct (166) still possessing the BCE-1 site
fected CTGF promoter/SEAP reporter constructs intoshowed abundant basal promoter activity (Fig. 2B).
mesangial cells. Either the deletion or mutation of aHowever, surprisingly, a deletion construct (110) from
which the BCE-1 site was removed but still possessed consensus SMAD binding element in the CTGF pro-
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Fig. 4. The Sp1 inhibitor mithramycin has no effect on basal CTGF
protein expression in mesangial cells. Cells were incubated for 6 hours
with or without 150 mmol/L mithramycin [30] as indicated, and cell
layers were subjected to Western blot analysis with a rabbit anti-CTGF
antibody [23] as described in the Methods section. As a control to
verify activity of mithramycin, scleroderma fibroblasts (SSc), in which
mithramycin reduces CTGF protein expression, were analyzed simulta-
neously (Leask et al, manuscript submitted for publication).
Fig. 5. Effect of protein kinase C (PKC), extracellular signal regulated
kinase (MEK) and tyrosine kinase inhibitors on basal and TGF-–
induced CTGF promoter activity in mesangial cells with () or withoutmoter (Fig. 2B, construct166 or SMAD) abolished the
( ) TGF-. Cells were transfected with CTGF promoter/SEAP re-ability of TGF- to induce CTGF promoter activity in
porter constructs (805 or BCE; Fig. 2A), as indicated. After a serum
mesangial cells. Intriguingly, we also found that mutation starvation step, cells were then incubated for 45 minutes with or without
10 mol/L of the tyrosine kinase inhibitor genistein (GEN), 10 mol/Lof the SMAD element reduced constitutive CTGF pro-
of the MEK1 and 2 inhibitor U0126, 50 mol/L of the MEK1 inhibitormoter activity. Collectively, these results suggest that the PD98059 (PD), 10 mol/L of the general PKC inhibitor bisinolylmalei-
SMAD recognition sequence in the CTGF promoter is mide (BIS) or 10 mol/L of the PKC inhibitor Go 6983 (Go). NO INH
denotes that no inhibitor added. Then, cells were incubated for annecessary for both basal and TGF-–induced CTGF
additional 24 hours with or without 5 ng/mL TGF-1. Then reportertranscription in mesangial cells. These results are in con- gene expression was assayed as described in the Methods section, and
standardized to a cotransfected CMV--galactosidase internal control.trast to the situation in normal and scleroderma dermal
Average expression values 
 SEM (N  6) are shown. **The drugfibroblasts where mutation of the SMAD element does
evaluated statistically significantly (P  0.01) reduces CTGF promoter
not affect basal promoter activity, but rather only affects activity both in the presence and absence of added TGF-.
TGF-–induced CTGF promoter activity [7]. To verify
the relevance of the SMADs to CTGF promoter activity
in mesangial cells, the full-length CTGF promoter/SEAP
CTGF induction requires ras/MEK/ERK, tyrosinereporter construct (805; Fig. 2A) was cotransfected
kinase, protein kinase Cwith empty expression vector, or vectors encoding the
Given that pathways other than SMADs are knowninhibitory SMADs SMAD6 or SMAD7 [reviewed in 25,
to be involved in the TGF- induction of gene expres-41]. These inhibitory SMADs block phosphorylation of
sion, we decided to investigate further the contributionsignaling SMADs at the level of receptor. Cotransfection
that these pathways might play in CTGF expression. Forof SMAD6 into mesangial cells had no effect on basal
example, TGF- has been shown to activate the MAPor TGF-–induced CTGF promoter activity (Fig. 4).
kinase pathway in mesangial cells [44]. To begin to inves-Confirming our results with the CTGF promoter con-
tigate the relevance of these pathways to the CTGFstruct bearing a mutated SMAD recognition sequence
gene regulation in mesangial cells, mesangial cells were
(SMAD; Fig. 2B), cotransfection of SMAD7 reduced
transfected with the full-length CTGF promoter/SEAP
basal CTGF promoter activity and the TGF-–induced reporter construct (805; Fig. 2A) and the ability of
promoter activity (Fig. 4). SMAD7 did not completely known signaling inhibitors to affect basal and TGF-–
block the TGF-–induction of CTGF, which is consistent induced CTGF promoter activity was tested. Preincuba-
with data previously obtained with fibroblasts [7], pre- tion of mesangial cells for 45 minutes with either the
sumably because SMAD7 protein generated from our MEK1 and 2 inhibitor U0126 [45], the tyrosine kinase
transfected construct was expressed in insufficient quan- inhibitor genistein [46], or the serine/threonine protein
tities to completely suppress the ability of TGF- recep- kinase C (PKC) inhibitors bisinolylmaleimide [47] and
tor to activate signaling SMADs. The incomplete sup- Go 6983 [48], potently reduced the ability of TGF- to
pression of the TGF- induction of CTGF observed in induce CTGF promoter activity (Fig. 5). In addition,
our experiments is consistent with results obtained in these inhibitors reduced basal CTGF promoter activity.
other studies that used SMAD7 overexpression systems These inhibitors were not acting through the BCE-1 site
to modulate the effects of TGF- on natural promoters as, when an otherwise wild-type promoter/reporter con-
[42, 43]. Collectively, these data point to a central role for struct bearing a mutated BCE-1 site was transfected into
SMAD-dependent signaling in CTGF gene expression in mesangial cells, mutating this element did not impair the
ability of these agents to reduce basal promoter activitymesangial cells.
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Fig. 7. Effect of PKC, MEK and tyrosine kinase inhibitors on basal and
TGF-–induced CTGF protein expression in mesangial cells: Western
analysis. After a serum-starvation step, cells were incubated for 45
minutes with the general PKC inhibitor bisinolylmaleimide (BIS), the
MEK inhibitor U0126 or the tyrosine kinase inhibitor genistein (GEN),
in concentrations indicated. After further incubation for 24 hours with
or without 5 ng/mL TGF-1, cells were assayed for CTGF protein
expression with a chicken anti-CTGF antibody [35] as described in the
Methods section. Addition of all three inhibitors reduced basal and
TGF-–induced CTGF expression.
Fig. 6. Dominant negative protein kinase C  affects CTGF expression
in mesangial cells. The full-length CTGF promoter/SEAP reporter con-
struct (805; Fig. 2A) was transfected into mesangial cells along with
empty expression vector, or expression vectors encoding dominant neg-
tyrosine kinase and MEK inhibitors to block the TGF-ative ras (ras), protein kinase C  (dnPKC) or protein kinase C 
(dnPKC). After transfection, serum starvation and a 24-hour incuba- induction of CTGF protein by Western and immunoflu-
tion period in the presence ( ) or absence () of 5 ng/mL TGF-1, orescence analyses (Figs. 7 and 8). By Western analysis,media were assayed for reporter activity as described in the Methods
incubation of cells with bisinolylmaleimide, U0126 orsection. Average expression values 
 SEM (N  6) are shown. **Co-
transfection of dnPKC significantly (P 0.01) reduces TGF-–induced genistein with or without subsequent TGF- treatment
CTGF promoter activity and dnras reduces (P  0.01) basal and TGF- for 24 hours potently reduced CTGF protein expression
–induced CTGF promoter activity.
(Fig. 7). Similarly, preincubation with the same inhibi-
tors, plus an additional tyrosine kinase inhibitor, herbi-
mycin [51], blocked the induction of intracellular CTGF
protein present in the Golgi apparatus (Fig. 8) [35]. Col-or block the TGF- induction of CTGF (Fig. 5). This
latter result was not surprising as the BCE-1 element lectively, our inhibitor data suggest that ras/MEK/ERK,
tyrosine kinase, and PKC activity are necessary for thewas not required for the TGF- induction of CTGF
(Fig. 2) [7, 19]. TGF- induction of CTGF in mesangial cells.
Intriguingly, the MEK1 inhibitor PD98059 did not af-
Inhibiting MAPK action does not preventfect the TGF- induction of CTGF [49], suggesting that
SMAD phosphorylationthe TGF- induction of CTGF in mesangial cells requires
MEK2, but not MEK1. To further verify our data exam- The ras/MEK/ERK signaling cascade has been shown
to be an important mediator of TGF- signaling, but theining the role of ras/MEK/ERK in the TGF-–induction
of CTGF in mesangial cells, expression vectors encoding role of this pathway in directly affecting SMADs remains
unclear. To investigate whether the ras/MEK/ERK cas-dominant negative versions of ras were used (N17), pro-
tein kinase C  or  [50]. As anticipated, transfection of cade blocked SMAD-dependent events, two approaches
were chosen.dominant negative ras potently reduced basal and TGF-
–induced CTGF promoter activity (dnras; Fig. 6). First, we assessed if the SMAD recognition sequence
in the CTGF promoter was required for the ability ofTransfection of dominant negative PKC  partially, but
significantly (P  0.05) reduced the TGF- induction of U0126 to reduce basal CTGF expression. Removal of the
SMAD recognition sequence did not impair the ability ofCTGF promoter activity (dnPKC; Fig. 6). Conversely,
dominant negative protein kinase C  had no such effect U0126 to reduce basal CTGF expression, as U0126 was
able to reduce activity of a full-length (805 to 17)on CTGF induction (dnPKC; Fig. 6). Thus, the ras/
MEK/ERK signaling cascade, in a MEK2-dependent CTGF promoter construct bearing a mutated SMAD
site (Fig. 9). Thus, ras/MEK/ERK signaling mechanismsmechanism, and PKC seem necessary for the TGF-–
mediated induction of CTGF promoter activity in rat modify CTGF gene expression at least in part through
a SMAD-independent mechanism.mesangial cells.
To further support our results examining CTGF pro- Second, we assessed the ability of U0126 to reduce
phosphorylation of SMAD3, which is a measure ofmoter expression, we examined the ability of these PKC,
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Fig. 8. Effect of PKC, MEK and tyrosine kinase inhibitors on basal and TGF-–induced CTGF expression in mesangial cells: Immunofluorescence
analysis. Cells were incubated in the presence or absence of 25 ng/mL TGF-2 (NO TGF or TGF, respectively) with or without 45 minute
pretreatment with 1 mol/L herbimycin (TGFHERB), 10 mol/L genistein (TGFGEN), 10 mol/L U0126 (TGFU0126) or 10 mol/L
bisinolylmaleimide (TGFBIS). Twenty-four hours after TGF- addition, cells were fixed and stained with a human anti-CTGF antibody [23]
and a Texas-Red-conjugated anti-human antibody as described in the Methods section.
Fig. 10. SMAD 3 phosphorylation (SMAD3-P) is not blocked by
U0126. Mesangial cells were transfected with expression vector encod-
ing FLAG tagged SMAD3. Proteins were phosphorylated in the pres-
ence of 32P-orthophosphate and 2.5 ng/mL TGF-2, and FLAG-tagged
SMAD3 was immunoprecipitated as described in the Methods section.
Before the addition of TGF-, cells were preincubated for 45 minutes
with 10 mol/L U0126 as indicated.
Fig. 9. Effect of mutating the CTGF promoter’s SMAD binding ele-
ment on the repression of CTGF promoter activity by signaling inhibi-
tors. As described in the Methods section and Figure 2, a CTGF pro-
moter/SEAP reporter construct bearing a mutated SMAD site (Fig.
2A, SMAD) was transfected into mesangial cells and, after a serum mol/L U0126 for 45 minutes. Cells were then treated
starvation step, cells were treated with inhibitors for 24 hours, as de- with or without TGF- for 15 and 30 minutes. Total
scribed in Figure 5. Removal of the SMAD element does not impair
protein was then harvested, and equal counts of radioac-the ability of PKC, MEK or tyrosine kinase inhibitors to reduce basal
CTGF promoter activity. **The drug evaluated gives statistically sig- tivity were immunoprecipitated with an anti-FLAG anti-
nificantly (P  0.01) reduces CTGF promoter activity both in the pres- body. After extensively washing the beads, FLAG-tagged
ence or absence of added TGF-.
SMAD3 was then eluted in sample buffer and subjected
to SDS-PAGE. Gels were dried, and subjected to autora-
diography to detect labeled, phosphorylated SMAD3.
Transfected SMAD3 was phosphorylated even in theSMAD3 activation [52]. SMAD3 was selected for this
study as it was previously shown that TGF- induction absence of TGF- (Fig. 10), consistent with the idea that
SMADs are constitutively active in this cell type. Thisof CTGF does not occur in SMAD3 knockout fibroblasts
[7]. A construct encoding FLAG-tagged SMAD3 was result presumably reflects that TGF- is constitutively
expressed by mesangial cells [53]. A 15 minute treatmenttransfected into mesangial cells. After 18 hours, cells
were incubated for two hours in the presence of 32P- of cells with TGF- induced additional phosphorylation
of SMAD3 that was reduced after 30 minutes of treat-orthophosphate. Cells were then incubated with 10
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ment (Fig. 10). Phosphorylation of SMAD3 was not lation. Our observations are similar to a study in HaCaT
cells, in which Hu et al found SMADs were required forblocked by U0126 (Fig. 10). Collectively, these results
suggest that ras/MEK/ERK modulates CTGF expression the TGF- induction of p21 [55]. This group also found
that MEK inhibitors had no effect on SMAD activity,independently of SMADs. Combined with our previous
data showing that, in mesangial cells, removal of the as visualized by DNA binding, nuclear localization and
interaction with p300. Thus, they concluded that SMADs,SMAD binding site completely abolished the TGF-
induction of CTGF, these results suggest that activation although necessary for the TGF- induction of CTGF
through ras/MEK/ERK, were more accurately thoughtof SMADs is necessary, but insufficient, for exogenously
added TGF- to induce CTGF expression through ras/ of as potentiators of the ability of TGF- to activate
p21 gene expression through ras/MEK/ERK. That is,MEK/ERK.
SMADs are necessary but not sufficient to activate ex-
pression of target genes. Also, a similar study noticed
DISCUSSION
synergistic cooperation between SMADs and ras/MEK/
Mesangial cells are useful models for the events lead- ERK in induction of a target gene, suggesting that ras/
ing to the onset of fibrosis, as they are not inherently MEK/ERK may act to modulate factors other than
myofibroblastic (that is, they are non-fibrotic), but can be SMADs [32]. It remains to be seen through which tran-
transformed into alpha-smooth muscle actin-expressing, scription factor(s) MAP kinase acts to modulate CTGF
pro-fibrotic myofibroblasts by TGF- treatment [12]. expression. Apart from the SMAD binding element,
Our studies have identified a central role of SMADs in there is at least one other element in the CTGF promoter
TGF-–induced CTGF gene regulation in dermal fibro- necessary for its induction by TGF- [19]. The identity
blasts and mesangial cells [7]. However, SMADs are of this additional factor/element and the potential contri-
generally involved in TGF- gene regulation [reviewed bution of ras/MEK/ERK to its regulation are currently
in 25, 26] and signaling, and therefore might not be good under investigation. However, preliminary data suggest
targets for drug intervention. For example, SMAD3 that ras/MEK/ERK indeed is operating through this ad-
knockout mice die soon after birth due to a severely ditional motif (Y. Chen and A. Leask, unpublished ob-
immunocompromised state resulting in extreme infec- servations).
tion [54]. In addition, although SMADs are apparently Our results implicating ras/MEK/ERK in TGF-–
involved in the onset of fibrosis, SMADs do not seem induced CTGF expression are in good agreement with
to be involved in maintaining sustained fibrosis [7]. a recent finding that ras/MEK/ERK is stimulated by
SMADs alone do not activate transcription. Rather, TGF- in mesangial cells [44, 56] and is involved with the
the current dogma is that SMADs activate gene expres- TGF- induction of fibronectin in this cell type [44, 56].
sion through the recruitment of transcription factors to Similarly, high glucose has been shown to stimulate PKC,
the promoter of interest [26]. Thus, SMADs are neces- which in turn can stimulate MEK/ERK [57, 58]. It is
sary but not sufficient for activation of target genes; possible that identifying how TGF- stimulates the PKC
they act synergistically with other signaling cascades and or ras/MEK/ERK signaling cascades might lead to an
transcription factors to activate gene expression. To this effective target for drug development.
end, our studies of CTGF expression using cultured mes- Our data examining signaling pathways involved in
angial cells have identified the ras/MEK/ERK signaling CTGF expression in mesangial cells are in good agree-
cascade, specifically MEK2, ras and PKC as being key ment with some recent data, published while this manu-
players in CTGF induction. In addition, we showed that script was in preparation, regarding CTGF gene expres-
deletion of a SMAD binding site, previously shown to sion in lung fibroblasts [59]. This recent report examined
be functional and to bind SMAD proteins in fibroblasts the effect of pharmacological inhibitors on CTGF pro-
[7], in the CTGF promoter abolished the TGF- induc- tein and mRNA expression and found that PKC, ras and
tion of CTGF. Thus, SMADs are absolutely required tyrosine kinase activities seemed to be important in the
for the TGF- induction of CTGF (consistent with their TGF- induction of CTGF [59]. Our current study sub-
proposed role in recruitment of transcription factors to stantially extends these observations. First, we examined
the promoter), although ras/MEK/ERK also are re- CTGF gene regulation in a different cell type, namely
quired for the TGF-–induction of CTGF (consistent kidney mesangial cells. We also assessed the effect of
with a proposed role in activating other transcription not only pharmacological inhibitors, but also dominant
factors; Fig. 5). Thus, signaling cascades such as ras/ negative versions of signaling components, namely ras,
MEK/ERK can be essential for the TGF- induction of PKC  and , on CTGF promoter activity. The involve-
genes without directly affecting SMAD activity. This ment of MAP kinase in CTGF gene expression was as-
interpretation is consistent with our observation that a sessed, we found that that MEK2, but not MEK1, is
MAP kinase inhibitor blocked basal and TGF-–induced involved in CTGF gene expression. In addition, the ef-
fect of MAP kinase on CTGF gene expression seemsCTGF expression but did not block SMAD3 phosphory-
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